CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
NEOGAP has created a personalized T cell therapy for solid tumors, utilizing advanced machine learning and neoantigen-driven stimulation to produce tumor-reactive T cells. This innovative approach aims to treat various cancer types by re-infusing tailored T cells that target and destroy cancer cells while sparing healt…
NEOGAP has developed a groundbreaking personalised adoptive T cell therapy for treating solid tumours based on two proprietary technologies:
PIOR machine learning software and EpiTCer.
This cancer immunotherapy consists of producing personalised Tumour Trained Lymphocytes (pTTL), which are autologous T-cells harvested from regional lymph nodes, subjected to a neoantigen-driven T-cell stimulation technology to deliver highly tumour-reactive T-cell clones (pTTLs). pTTLs are re-infused to the patie…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
